Beyond Belviq: Reinventing Arena To Focus On Phase II Candidates
Executive Summary
Dr. Amit Munshi, new CEO of Arena Pharmaceuticals, has already made several changes in the company’s focus and direction as it reduces its commitment to Belviq. He talked to Mike Ward about progress to date.
You may also be interested in...
Arena Rises With Post-Belviq Pipeline
Arena's valuation rose more than four-fold in 2017. CEO Amit Munshi discusses his plans for lead programs ralinepag and etrasimod following cost cutting and fundraising, and handing over rights to weight loss product Belviq to Eisai.
If Orexigen Disappears, Who's Left In The Obesity Market?
Orexigen, one of just five biopharma companies with an obesity product on the market, has become concerned about its ability to stay in business. Even so, the misfortune of several firms hasn't dissuaded others, including Novo Nordisk, from investing in the potentially large weight-loss market.
Deal Watch: Taking Care Of Business Before J.P. Morgan
Under Momenta/CSL autoimmune partnership, Momenta can opt in to co-development or commercialization on recombinant Fc receptor modulator or just earn a revenue stream from CSL’s efforts with the preclinical candidate. Pieris and Servier sign broad-based immuno-oncology collaboration, while Arena hands off the disappointing Belviq to Eisai.